Drug Profile
Research programme: stem cell therapies - AstraZeneca/University System of Maryland
Latest Information Update: 06 Aug 2021
Price :
$50
*
At a glance
- Originator MedImmune; University System of Maryland
- Developer AstraZeneca; University System of Maryland
- Class Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cardiovascular disorders; Metabolic disorders
Most Recent Events
- 28 Jun 2018 No recent reports of development identified for research development in Cardiovascular-disorders in USA
- 28 Jun 2018 No recent reports of development identified for research development in Metabolic-disorders in USA
- 08 May 2014 Early research in Cardiovascular disorders in USA (unspecified route)